Crossmark

Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review

Crossref DOI link: https://doi.org/10.1007/s11523-018-0558-1

Published Online: 2018-03-20

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rossi, Cédric https://orcid.org/0000-0003-3717-7961
Chrétien, Marie-Lorraine

Casasnovas, René-Olivier
License Information

Text and Data Mining valid from 2018-03-20
More Information

Article History

First Online: 20 March 2018

Compliance with Ethical Standards

:

: None.

: R.-O. Casasnovas received honoraria from Roche, Takeda, Gilead, and research funding from Roche and Gilead, and had a consulting role for Roche, Takeda, Gilead, Abbvie, BMS, and Merck. C. Rossi had a consulting role for Takeda and research funding from Roche. M.-L. Chrétien has no disclosures to declare.